The clinical pharmacology of antiretrovirals in development.

Article Details

Citation
Copy to clipboard

Winston A, Mallon PW, Boffito M

The clinical pharmacology of antiretrovirals in development.

Expert Opin Drug Metab Toxicol. 2006 Jun;2(3):447-58.

PubMed ID
16863445 [ View in PubMed
]
Abstract

Drugs in development for the management of HIV type 1 (HIV-1) infection include agents in existing classes and agents of novel classes. Of existing classes, new protease inhibitors, nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors are in development. Novel therapeutic approaches include the development of chemokine receptor (CCR)5 antagonists, integrase inhibitors and maturation inhibitors. CCR5 antagonists are thought to inhibit HIV-1 entry into host cells by occupying a specific site on the CCR5 receptor, preventing attachment of the HIV-1 envelope protein gp120. Integrase inhibitors are small synthetically prepared molecules that block RNA/DNA interactions and modify protein or enzyme synthesis. Data on the pharmacokinetics and pharmacodynamics of these new antiretroviral agents continue to generate interest. This review reports the known data on the pharmacokinetics of experimental antiretrovirals, and describe the main drug-drug interactions studied so far.

DrugBank Data that Cites this Article

Drugs